Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.35 USD
-0.03 (-1.26%)
Updated Aug 28, 2024 12:26 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CLLS 2.35 -0.03(-1.26%)
Will CLLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLLS
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cellectis (CLLS) Upgraded to Buy: Here's Why
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Other News for CLLS
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis Reveals Promising Cancer Therapy Breakthrough
Cibus to Participate in Upcoming August Investor Events
Cellectis SA: Strong Buy Rating on Robust Pipeline and Financial Stability
Cibus: Q2 Earnings Snapshot